What is GeNO?
GeNO LLC operates at the intersection of advanced chemistry and medical device engineering, focusing on the development of next-generation inhaled nitric oxide (NO) products. The company's core innovation, the GeNOsyl drug delivery technology, utilizes a proprietary chemical process that generates nitric oxide from nitrogen dioxide, effectively mitigating the toxic co-delivery of nitrogen dioxide associated with conventional systems. This technological edge allows for precise, intra-breath concentration delivery, catering to both acute hospital environments and long-term outpatient needs. With active Investigational New Drug Applications (INDs) and a focus on pulmonary arterial hypertension, GeNO is positioned as a high-authority player in the respiratory therapeutics market, emphasizing safety, efficacy, and clinical simplicity.
How much funding has GeNO raised?
GeNO has raised a total of $54.8M across 4 funding rounds:
Private Equity
$2.1M
Private Equity
$8M
Private Equity
$14.7M
Private Equity
$29.9M
Private Equity (2009): $2.1M, investors not publicly disclosed
Private Equity (2011): $8M, investors not publicly disclosed
Private Equity (2013): $14.7M, investors not publicly disclosed
Private Equity (2017): $29.9M, investors not publicly disclosed
Key Investors in GeNO
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for GeNO?
With the recent influx of capital, GeNO is well-positioned to accelerate its clinical trial pipeline and expand the reach of its GeNOsyl platform. The strategic roadmap likely involves finalizing the regulatory pathway for its lead product, GeNOsyl Acute DS, while simultaneously exploring broader diagnostic applications for right heart catheterization. As the company matures, the focus will shift toward commercialization and establishing a dominant footprint in the pulmonary disease sector. By maintaining its commitment to rigorous chemical precision and user-centric design, GeNO is poised to disrupt the current standard of care, offering a safer, more reliable alternative for patients requiring nitric oxide therapy in diverse clinical settings.
See full GeNO company page
